Trial Profile
Phase II Dual-Cohort Study Evaluating the Effects of Pembrolizumab in the Presence of Gut Microbiota Modulation With EDP1503 in Advanced Melanoma Naive or Refractory to Anti-PD1 Antibody
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs EDP-1503 (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 26 Jan 2024 Planned End Date changed from 2 Nov 2023 to 2 Nov 2027.
- 26 Jan 2024 Planned primary completion date changed from 2 Nov 2023 to 2 Nov 2027.
- 26 Apr 2023 Planned primary completion date changed from 2 Nov 2022 to 2 Nov 2023.